Actinium Pharmaceuticals Inc. Watch

from 8-K 22 pages Investors’ Rights Agreement by and Between Actinium Pharmaceuticals, Inc. and Memorial Sloan Kettering Cancer Center

from S-1 2 pages Letter Agreement, Dated September 4, 2013, Between Actinium Pharmaceuticals, Inc. and Sloan-Kettering Institute for Cancer Research.**

from 8-K/A 12 pages Clinical Trial Agreement

from 8-K/A 4 pages Reference Is Made to Certain Obligations of Actinium Pharmaceuticals, Inc. ("Api") to Sloan-Kettering Institute for Cancer Research ("Ski") and Its Related or Affiliated Entities (Such Entities, Together With Ski, Memorial Sloan-Kettering Cancer Institute, Inc. ("Mskcc") and Memorial Hospital for Cancer and Allied Diseases, the "Ski Parties") in the Approximate Amount of $260,000 on the Date Hereof (The "Current Obligations"), Consisting of Obligations Under (I) Section 5 and Section 6.3 of the License, Development and Commercialization Agreement, Dated as of February 11, 2002, Between Ski, Api and Actinium Pharmaceuticals, Ltd. (The "License Agreement"); and (II) Section 5 of the Clinical Trial Agreement, Dated as of February 26, 2006, Between Ski and Its Affiliate Memorial Hospital for Cancer and Allied Diseases and Api (The "Clinical Trial Agreement"). Prior to January 1, 2012, Api Will Incur Additional Obligations to Ski Under Section 5 and Section 6.3 of the License Agreement and May Incur Other Obligations to One or More of the Ski Parties for the Goods and/or Services Provided (The "Forbearance Period Obligations," the Forbearance Period Obligations, Together With the Current Obligations, the "Obligations")

from 8-K/A ~1 page Letter Agreement, Dated June 19, 2011, Between Actinium Pharmaceuticals, Inc. and Sloan-Kettering Institute for Cancer Research.

from 8-K/A 15 pages Clinical Trial Agreement

from 8-K/A 11 pages Clinical Trial Agreement, Dated January 18, 2001, Between Actinium Pharmaceuticals, Inc. and Memorial Sloan Kettering Cancer Center for the Purpose of Conducting a Clinical Trial Entitled ?Phase I/II Trial of 213bi-M195 and Cytarabine for Acute Myeloid Le

from 8-K/A 37 pages Monday, April 14, 2003 (3).max Monday, April 14, 2003 (3).max Monday, April 14, 2003 (3).max Monday, April 14, 2003 (3).max Monday, April 14, 2003 (3).max Monday, April 14, 2003 (3).max Monday, April 14, 2003 (3).max Monday, April 14, 2003 (3).max Monday, April 14, 2003 (3).max Monday, April 14, 2003 (3).max Monday, April 14, 2003 (3).max Monday, April 14, 2003 (3).max Monday, April 14, 2003 (3).max Monday, April 14, 2003 (3).max Monday, April 14, 2003 (3).max Monday, April 14, 2003 (3).max Monday, April 14, 2003 (3).max Monday, April 14, 2003 (3).max Monday, April 14, 2003 (3).max Monday, April 14, 2003 (3).max Monday, April 14, 2003 (3).max Monday, April 14, 2003 (3).max Monday, April 14, 2003 (3).max Monday, April 14, 2003 (3).max Monday, April 14, 2003 (3).max Monday, April 14, 2003 (3).max Monday, April 14, 2003 (3).max Monday, April 14, 2003 (3).max Monday, April 14, 2003 (3).max Monday, April 14, 2003 (3).max Monday, April 14, 2003 (3).max Monday, April 14, 2003 (3).max Monday, April 14, 2003 (3).max Monday, April 14, 2003 (3).max Monday, April 14, 2003 (3).max Monday, April 14, 2003 (3).max